Orient Europharma Trials

23 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Nanoplatin (demplatin pegraglumer) / NANO MRNA, Orient Europharma

NCT03771820 / 2018-003959-37: Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Recruiting

2a/2b

136

Europe, RoW

NC-6004, Nanoplatin, Pembrolizumab, Keytruda

NanoCarrier Co., Ltd., Orient Europharma Co., Ltd.

SCCHN

04/21

04/22

Ansimar (doxofylline) / ICE GROUP, Alitair Pharma

NCT06346691: Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease : A Randomized Crossover Study

Not yet recruiting

Doxofylline, Procaterol

Thammasat University

COPD

09/24

12/24

ChiCTR2400080121: Effect of doxofylline on recovery time of propofol: A prospective randomized controlled clinical trial

Not yet recruiting

Doxofylline 2 mg/kg (15 ml) IV postoperatively; Saline 15ml IV postoperatively

Taizhou Hospital of Zhejiang Province; Taizhou Hospital of Zhejiang Province, self-funded

None

ChiCTR2400080165: Effect of doxofylline on recovery time of sevoflurane: A prospective randomized controlled clinical trial

Not yet recruiting

Doxofylline 2 mg/kg (15 ml) and sugammadex sodium IV postoperatively; Saline 15ml and sugammadex sodium IV postoperatively

Taizhou Hospital of Zhejiang Province; Taizhou Hospital of Zhejiang Province, self-funded

None

ChiCTR2200063105: Effects of ultrasound-guided individualized PEEP combined with doxofylline on the protection of lung function during laparoscopic surgery and postoperative neurocognitive function in patients with COPD

Recruiting

N/A

108

conventional high tidal volume ventilation ;PEEP=5cmH2O ;individualized PEEP levels

The Second Affiliated Hospital of Fujian Medical University; The Second Affiliated Hospital of Fujian Medical University, High-level talent cultivation project in the Second Affiliated Hospital of Fujian Medical University, 2022GCC02

Chronic Obstructive Pulmonary Disease (COPD); Cognitive Impairment

NCT05154942: Vmax Detection of Acupuncture-doxofylline as a Whole Probe of CYP1A in Vivo

Not yet recruiting

N/A

DOXO+electroacupuncture

Shanghai Yueyang Integrated Medicine Hospital, Shanghai University of Traditional Chinese Medicine

Acupuncture, Drug Interaction

09/23

11/23

OvaRex (oregovomab) / CanariaBio

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms

09/25

08/27

QPT-ORE-004, NCT05335993: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Active, not recruiting

Oregovomab, MAb-B43.13, Monoclonal antibody B43.13, Niraparib, Zejula

CanariaBio Inc., Veristat, LLC

Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary

03/24

12/24

OPERA, NCT05407584: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting

RoW

Orevogomab+PLD, Orevogomab+Paclitaxel

Yonsei University, CanariaBio Inc.

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

05/24

11/24

QPT-ORE-006, NCT05605535: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Recruiting

RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Raptim Research Pvt. Ltd

Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma, Ovarian Serous Adenocarcinoma

09/24

05/26

NCT04938583: Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Recruiting

1b/2

RoW

Oregovomab, MAb-B43.13, Bevacizumab, Avastin, Paclitaxel, Taxol, Paxcel, Padexol, Carboplatin, Neoplatin

CanariaBio Inc., Korean Cancer Study Group

Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV

04/24

12/25

ORION-02, NCT04620954: Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Recruiting

1/2

RoW

Oregovomab, Nivolumab, Chemotherapy

National Cancer Centre, Singapore, OncoQuest Pharma USA Inc., Bristol-Myers Squibb

Epithelial Ovarian Cancer

07/22

Gatiflox (gatifloxacin) / Orient Europharma

ChiCTR-TRC-12002693: Comparative Study of Human Aqueous Humor Levels of Gatifloxacin 0.3% Eye Gel, Gatifloxacin 0.3% and Levofloxacin 0.5% Ophthalmic Solution after Topical Dosing

Completed

150

One drop of gatifloxacin 0.3% eye gel was administration ;One drop of gatifloxacin 0.3% ophthalmic solution ;One drop of levofloxacin 0.5% ophthalmic solution

Zhejiang University; Zhejiang University, Zhejiang Key Innovation Team Project of China (2009R50039); Zhejiang Key Laboratory Fund of China (2011E10006)

endoophthalmitis after cataract surgery

ChiCTR2500099433: Screening of dry eye scheme based on cyclosporine, dexamethasone, perfluoroethyloctane eye drops for the treatment of diabetes patients with cataract and interpretation of its internal mechanism

Not yet recruiting

N/A

120

Thirty patients (eyes) received postoperative treatment with cyclosporine eye drops four times a day for a total of one month, tobramycin dexamethasone eye drops, gatifloxacin eye drops ,recombinant bovine basic fibroblast growth factor ophthalmic gel three times a day for a total of two weeks, and Praprofen eye drops three times a day for a total of one month. ; Thirty patients (eyes) received postoperative treatment with perfluorohexaneoctane eye drops four times a day for a total of one month, tobramycin dexamethasone eye drops, gatifloxacin eye drops,recombinant bovine basic fibroblast growth factor ophthalmic gel three times a day for a total of two weeks, and praprofen eye drops three times a day for a total of one month. ; Thirty patients (eyes) received postoperative treatment with diquat sodium eye drops four times a day for one month, tobramycin dexamethasone eye drops, gatifloxacin eye drops,recombinant bovine basic fibroblast growth factor ophthalmic gel three times a day for two weeks, and Pralofen Eye Drops three times a day for one month.; Postoperative use of only tobramycin dexamethasone eye drops, gatifloxacin eye drops,recombinant bovine basic fibroblast growth factor ophthalmic gelthree times a day for 2 weeks, and Pralofen eye drops three times a day for 1 month, 30 cases (eyes).

The First People's Hospital of Zigong City; The First People's Hospital of Zigong City, Key R&D Technology Plan Project for High Quality Development of the First People's Hospital of Zigong City

Dry eye

NCT03625739: Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

Recruiting

N/A

800

RoW

anti-tuberculosis drug, Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Levofloxacin, Moxifloxacin, Gatifloxacin, Amikacin, Capreomycin, Kanamycin (Streptomycin), Ethionamide, Cycloserine, terizidone, Clofazimine, Bedaquiline, Delamanid, p-aminosalicylic acid, Imipenem-cilastatind, Amoxicillin-clavulanate, Thioacetazone

Beijing Children's Hospital, Shandong University, Hopital Universitaire Robert-Debre, Rennes University Hospital

Tuberculosis

10/26

12/26

Akalux (cetuximab sarotalocan) / Rakuten Medical

ASP-1929-301, NCT03769506 / 2018-002513-36: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Active, not recruiting

135

Japan, US, RoW

ASP-1929 Photoimmunotherapy, Physician's Choice SOC

Rakuten Medical, Inc.

Head and Neck Cancer

12/25

ECLIPSE, NCT06699212: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Recruiting

412

Japan, US, RoW

ASP-1929 Photoimmunotherapy, cetuximab sarotalocan, PIT690 Laser System, Pembrolizumab, Keytruda, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel

Rakuten Medical, Inc.

Recurrent Head and Neck Squamous Cell Carcinoma

09/28

NCT05265013: ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Terminated

RoW

ASP-1929 Photoimmunotherapy, cetuximab sarotalocan, PIT690 Laser System, pembrolizumab, Keytruda

Rakuten Medical, Inc.

Head and Neck Cancer

11/23

03/24

NCT05182866: ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Active, not recruiting

ASP-1929 Photoimmunotherapy

Rakuten Medical, Inc., Shimadzu Corporation, National Cancer Institute (NCI)

Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck

07/24

06/26

NCT06943664: Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Not yet recruiting

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810, Cetuximab Sarotalocan Sodium, ASP 1929, ASP-1929, ASP1929, Cet-IR700, Cetuximab-IR700 Conjugate RM-1929, RM-1929, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy, EBUS, Endobronchial Ultrasound, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Photoimmunotherapy, Photodynamic Light Therapy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Robotic Bronchoscopy, Robot-Assisted Bronchoscopy, Robotic-Assisted Bronchoscopy, Video-Assisted Thoracic Surgery, VATS, Video-Assisted Thoroscopic Surgery

Roswell Park Cancer Institute

Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

05/27

05/28

NCT04305795: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Active, not recruiting

1/2

200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929 PIT

Rakuten Medical, Inc.

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma

06/26

06/27

firibastat (QGC-001) / Quantum Genomics

2015-005607-92: An European study to assass safety and efficacy of a new drug in patients with worsening chronic heart failure.

Ongoing

Europe, RoW

Amino butane sulfonate Disulfure, QGC001, Capsule

QUANTUM GENOMICS, Quantum Genomics, QUANTUM GENOMICS, Quantum Genomics

Patient with worsening chronic heart failure with left ventricular systolic dysfunction, Patient with worsening chronic heart failure, Diseases [C] - Cardiovascular Diseases [C14]

QUORUM, NCT03715998 / 2018-003146-17: Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Completed

295

Europe

Ramipril, Firibastat, QGC001

Quantum Genomics SA

Myocardial Infarction

07/21

ezetimibe/pitavastatin (1PC111) / Orient Europharma

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Nanoplatin (demplatin pegraglumer) / NANO MRNA, Orient Europharma

NCT03771820 / 2018-003959-37: Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Recruiting

2a/2b

136

Europe, RoW

NC-6004, Nanoplatin, Pembrolizumab, Keytruda

NanoCarrier Co., Ltd., Orient Europharma Co., Ltd.

SCCHN

04/21

04/22

Ansimar (doxofylline) / ICE GROUP, Alitair Pharma

NCT06346691: Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease : A Randomized Crossover Study

Not yet recruiting

Doxofylline, Procaterol

Thammasat University

COPD

09/24

12/24

ChiCTR2400080121: Effect of doxofylline on recovery time of propofol: A prospective randomized controlled clinical trial

Not yet recruiting

Doxofylline 2 mg/kg (15 ml) IV postoperatively; Saline 15ml IV postoperatively

Taizhou Hospital of Zhejiang Province; Taizhou Hospital of Zhejiang Province, self-funded

None

ChiCTR2400080165: Effect of doxofylline on recovery time of sevoflurane: A prospective randomized controlled clinical trial

Not yet recruiting

Doxofylline 2 mg/kg (15 ml) and sugammadex sodium IV postoperatively; Saline 15ml and sugammadex sodium IV postoperatively

Taizhou Hospital of Zhejiang Province; Taizhou Hospital of Zhejiang Province, self-funded

None

Recruiting

N/A

108

conventional high tidal volume ventilation ;PEEP=5cmH2O ;individualized PEEP levels

Chronic Obstructive Pulmonary Disease (COPD); Cognitive Impairment

NCT05154942: Vmax Detection of Acupuncture-doxofylline as a Whole Probe of CYP1A in Vivo

Not yet recruiting

N/A

DOXO+electroacupuncture

Shanghai Yueyang Integrated Medicine Hospital, Shanghai University of Traditional Chinese Medicine

Acupuncture, Drug Interaction

09/23

11/23

OvaRex (oregovomab) / CanariaBio

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

09/25

08/27

QPT-ORE-004, NCT05335993: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Active, not recruiting

Oregovomab, MAb-B43.13, Monoclonal antibody B43.13, Niraparib, Zejula

CanariaBio Inc., Veristat, LLC

03/24

12/24

OPERA, NCT05407584: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting

RoW

Orevogomab+PLD, Orevogomab+Paclitaxel

Yonsei University, CanariaBio Inc.

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

05/24

11/24

QPT-ORE-006, NCT05605535: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Recruiting

RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Raptim Research Pvt. Ltd

Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma, Ovarian Serous Adenocarcinoma

09/24

05/26

NCT04938583: Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Recruiting

1b/2

RoW

Oregovomab, MAb-B43.13, Bevacizumab, Avastin, Paclitaxel, Taxol, Paxcel, Padexol, Carboplatin, Neoplatin

CanariaBio Inc., Korean Cancer Study Group

Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV

04/24

12/25

ORION-02, NCT04620954: Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Recruiting

1/2

RoW

Oregovomab, Nivolumab, Chemotherapy

National Cancer Centre, Singapore, OncoQuest Pharma USA Inc., Bristol-Myers Squibb

Epithelial Ovarian Cancer

07/22

Gatiflox (gatifloxacin) / Orient Europharma

ChiCTR-TRC-12002693: Comparative Study of Human Aqueous Humor Levels of Gatifloxacin 0.3% Eye Gel, Gatifloxacin 0.3% and Levofloxacin 0.5% Ophthalmic Solution after Topical Dosing

Completed

150

One drop of gatifloxacin 0.3% eye gel was administration ;One drop of gatifloxacin 0.3% ophthalmic solution ;One drop of levofloxacin 0.5% ophthalmic solution

Zhejiang University; Zhejiang University, Zhejiang Key Innovation Team Project of China (2009R50039); Zhejiang Key Laboratory Fund of China (2011E10006)

endoophthalmitis after cataract surgery

Not yet recruiting

N/A

120

The First People's Hospital of Zigong City; The First People's Hospital of Zigong City, Key R&D Technology Plan Project for High Quality Development of the First People's Hospital of Zigong City

Dry eye

NCT03625739: Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

Recruiting

N/A

800

RoW

Beijing Children's Hospital, Shandong University, Hopital Universitaire Robert-Debre, Rennes University Hospital

Tuberculosis

10/26

12/26

Akalux (cetuximab sarotalocan) / Rakuten Medical

ASP-1929-301, NCT03769506 / 2018-002513-36: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Active, not recruiting

135

Japan, US, RoW

ASP-1929 Photoimmunotherapy, Physician's Choice SOC

Rakuten Medical, Inc.

Head and Neck Cancer

12/25

Recruiting

412

Japan, US, RoW

ASP-1929 Photoimmunotherapy, cetuximab sarotalocan, PIT690 Laser System, Pembrolizumab, Keytruda, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel

Rakuten Medical, Inc.

Recurrent Head and Neck Squamous Cell Carcinoma

09/28

NCT05265013: ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Terminated

RoW

ASP-1929 Photoimmunotherapy, cetuximab sarotalocan, PIT690 Laser System, pembrolizumab, Keytruda

Rakuten Medical, Inc.

Head and Neck Cancer

11/23

03/24

NCT05182866: ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Active, not recruiting

ASP-1929 Photoimmunotherapy

Rakuten Medical, Inc., Shimadzu Corporation, National Cancer Institute (NCI)

Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck

07/24

06/26

NCT06943664: Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Not yet recruiting

Roswell Park Cancer Institute

05/27

05/28

NCT04305795: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Active, not recruiting

1/2

200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929 PIT

Rakuten Medical, Inc.

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma

06/26

06/27

firibastat (QGC-001) / Quantum Genomics

2015-005607-92: An European study to assass safety and efficacy of a new drug in patients with worsening chronic heart failure.

Ongoing

Europe, RoW

Amino butane sulfonate Disulfure, QGC001, Capsule

QUANTUM GENOMICS, Quantum Genomics, QUANTUM GENOMICS, Quantum Genomics

Patient with worsening chronic heart failure with left ventricular systolic dysfunction, Patient with worsening chronic heart failure, Diseases [C] - Cardiovascular Diseases [C14]

QUORUM, NCT03715998 / 2018-003146-17: Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Completed

295

Europe

Ramipril, Firibastat, QGC001

Quantum Genomics SA

Myocardial Infarction

07/21

ezetimibe/pitavastatin (1PC111) / Orient Europharma

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites